𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen–positive hepatitis B

✍ Scribed by Robert A. de Man; Patrick Marcellin; Flavio Habal; Paul Desmond; Teresa Wright; Toby Rose; Regina Jurewicz; Clarence Young

Book ID
111721318
Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
219 KB
Volume
32
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Interferon α-2b with and without ribavir
Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen–positive chronic hepatitis B: A randomized study
✍ Chun-Jen Liu; Ming-Yang Lai; You-Chen Chao; Li-Ying Liao; Sien-Sing Yang; Tun-Je 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

To study whether interferon (IFN) ␣ and ribavirin combination therapy has a beneficial effect for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, we enrolled 119 such patients in a randomized study. Fifty-nine patients received 5 million units of IFN-␣2b daily for 4 weeks followed by 5 m

Early hepatitis B virus DNA reduction in
Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir
✍ Nancy Leung; Cheng-Yuan Peng; Hie-Won Hann; Jose Sollano; Judy Lao-Tan; Chao-Wei 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB 👁 2 views

This study was undertaken to compare the early antiviral activity and viral kinetic profiles of entecavir (ETV) versus adefovir (ADV) in hepatitis B e antigen positive nucleoside-naïve adults with chronic hepatitis B (CHB). Sixty-nine nucleoside-naïve CHB patients with baseline HBV DNA of 10(8) copi

A randomized controlled trial of thymosi
A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody—and hepatitis B virus DNA—positive chronic hepatitis B
✍ P Andreone; C Cursaro; A Gramenzi; C Zavaglia; I Rezakovic; E Altomare; R Severi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

ment for anti-HBe-positive chronic hepatitis. The benefit It has recently been shown that thymosin-a 1 (T-a 1 ), a of this agent in producing long-term inhibition of HBV synthetic polypeptide of thymic origin, is able to proreplication must be confirmed by future trials. (HEPAmote disease remission

A randomized, controlled trial of a 24-m
A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum
✍ P Lampertico; E Del Ninno; A Manzin; M F Donato; M G Rumi; G Lunghi; A Morabito; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 3 views

## Short-term interferon treatment of serum hepatitis B e anti- Chronic infection with precore mutant strains of hepatitis B virus (HBV) resulting in infection with hepatitis B surface gen (HBeAg)-negative carriers with serum hepatitis B virus (HBV) DNA and histological features of chronic hepatit